Home › Research › Biomarkers
Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI
Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, Senjem ML, Jordan L et al.. Neurology, 2013-05-03
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective We describe the operationalization of the National Institute on Aging-Alzheimer's Association (NIA-AA) workgroup diagnostic guidelines pertaining to Alzheimer disease (AD) dementia in a large multicenter group of subjects with AD dementia. Methods Subjects with AD dementia from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with at least 1 amyloid biomarker (n = 211) were included in this report. Biomarker data from CSF Aβ42, amyloid PET, fluorodeoxyglucose-PET, and MRI were examined. The biomarker results were assessed on a per-patient basis and the subject categorization as defined in the NIA-AA workgroup guidelines was determined. Results When using a requirement that subjects have a positive amyloid biomarker and single neuronal injury marker having an AD pattern, 87% (48% for both neuronal injury biomarkers) of the subjects could be categorized as "high probability" for AD. Amyloid status of the combined Pittsburgh compound B-PET and CSF results showed an amyloid-negative rate of 10% in the AD group. In the ADNI AD group, 5 of 92 subjects fit the category "dementia unlikely due to AD" when at least one neuronal injury marker was negative. Conclusions A large proportion of subjects with AD dementia in ADNI may be categorized more definitively as high-probability AD using the proposed biomarker scheme in the NIA-AA criteria. A minority of subjects may be excluded from the diagnosis of AD by using biomarkers in clinically categorized AD subjects. In a well-defined AD dementia population, significant biomarker inconsistency can be seen on a per-patient basis.
What this study adds
Evidence grade: Low
The record lists 211 participants. Applying the NIA-AA biomarker criteria to 211 people with Alzheimer's dementia from ADNI, 87% could be classified as high-probability Alzheimer's disease when requiring a positive amyloid biomarker and one neuronal injury marker. A minority could be classified as dementia unlikely due to Alzheimer's, showing that the criteria can categorize most but not all cases.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lowe, V. J., Peller, P. J., Weigand, S. D., Montoya Quintero, C., Tosakulwong, N., Vemuri, P., et al. (2013). Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology. https://doi.org/10.1212/wnl.0b013e318295d6cf
Vancouver
Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, et al. Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology. 2013. doi:10.1212/wnl.0b013e318295d6cf. PMID: 23645596.
BibTeX
@article{lowe2013-23645596,
author = {Lowe, V. J. and Peller, P. J. and Weigand, S. D. and Montoya Quintero, C. and Tosakulwong, N. and Vemuri, P. and Senjem, M. L. and Jordan, L. and others},
title = {{Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI}},
journal = {Neurology},
year = {2013},
doi = {10.1212/wnl.0b013e318295d6cf},
pmid = {23645596},
url = {https://doi.org/10.1212/wnl.0b013e318295d6cf}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The biomarker results were assessed on a per-patient basis and the subject categorization as defined in the NIA-AA workgroup guidelines was determined.
- Results When using a requirement that subjects have a positive amyloid biomarker and single neuronal injury marker having an AD pattern, 87% (48% for both neuronal injury biomarkers) of the subjects could be categorized as "high probability" for AD.
- Amyloid status of the combined Pittsburgh compound B-PET and CSF results showed an amyloid-negative rate of 10% in the AD group.
- In a well-defined AD dementia population, significant biomarker inconsistency can be seen on a per-patient basis.
Why it matters
Applying the NIA-AA biomarker criteria to 211 people with Alzheimer's dementia from ADNI, 87% could be classified as high-probability Alzheimer's disease when requiring a positive amyloid biomarker and one neuronal injury marker. A minority could be classified as dementia unlikely due to Alzheimer's, showing that the criteria can categorize most but not all cases.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants211
- Evidence strengthLow
How this study scored 52/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 211 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 51 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.4 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 3 / 6 | Cited 5.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Ronald Carl Petersen: h-index 209 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23645596) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0b013e318295d6cf
- PubMed: 23645596
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also in Biomarkers
147 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.